BioSpherix, a global leader in Cytocentric® environmental control systems, has announced the launch of its new state-of-the-art facility, The Center for Cytocentric® Technology (CCT), located in Parish, NY. The facility houses a newly operational Xvivo System® and will serve as a GMP-level CDMO/CRO service center, expanding BioSpherix’s capabilities to support advanced cell and gene therapy development throughout the upstate NY region.

Strategically positioned near the rapidly growing biotechnology hubs in Syracuse and Rochester NY, CCT strengthens BioSpherix’s presence within an expanding life sciences ecosystem and reinforces its commitment to advancing access to advanced biotechnology tools and infrastructure across the region.

This Xvivo System, along with other BioSpherix systems found globally, is purpose-built to provide an aseptic, closed, and optimized processing environment for cell culture and manufacturing. By providing a space for all cell handling processes from start to finish, the Xvivo System replaces the need for brick-and-mortar cleanrooms and traditional laboratories that expose cells to ambient air and fluctuating, suboptimal environmental conditions.

Unlike conventional cleanrooms and laboratories that rely heavily on chemical disinfectants, the Xvivo System integrates patented self-sanitizing technology that minimizes biocide use while preserving sterility and protecting cells from unnecessary chemical exposure.

“The opening of the Center for Cytocentric® Technology marks a pivotal step forward for both BioSpherix and the broader cell and gene therapy community. By utilizing our Xvivo System® to provide GMP-level CDMO and CRO services in a fully closed, physiologically accurate environment, we are redefining how advanced therapies can be developed and manufactured. Our goal is to provide innovators across upstate New York and beyond with direct access to scalable, reproducible, and truly Cytocentric solutions that improve both scientific outcomes and patient impact.” – Syed Ahmed Mustafa, President/CEO of BioSpherix

The modular nature of the Xvivo System allows is to be configured around virtually any cell workflow and customized to incorporate third-party equipment. This Cytocentric approach to cell culture and manufacturing enhances reproducibility, improves cell viability, and supports more physiologically relevant data that can translate more effectively into clinical outcomes.

CCT will function as a GMP-level CDMO/CRO service location, offering support for early-state development, process optimization, and GMP-aligned manufacturing under tightly regulated, physiologic conditions without the need for a traditional cleanroom footprint.

Key features of CCT:

• GMP-level CDMO/CRO services for cell and gene therapy development
• Integration of the Xvivo System GMP X2 for closed, controlled, and Cytocentric environmental control
• Precise regulation of oxygen, carbon dioxide, temperature, humidity, and limit control measurements for particles, VHPs, and VOCs
• Strategic proximity to the growing biotechnology hubs in Syracuse and Rochester NY

“Cells and tissues in traditional room air culture, even in a cleanroom, are subjected to highly variable and non-physiologic conditions on a routine basis. This facility provides the full-time control of conditions that cells need for better growth and more reproducible results.” – Alicia Henn, PhD MBA, Chief Scientific Officer of BioSpherix

CCT is now operational and accepting CDMO and CRO partnerships for organizations seeking reproducible, scalable, and physiologically relevant cell and gene therapy workflows. A formal ribbon-cutting ceremony will be held in April.

Media Contact: